Insights

BioInvent International Aktiebolag

Nasdaq Stockholm · LEI 549300E7QRHEF2IJUY10· Fiscal year 2025

Staff cost per employee
Not disclosed
Employees
Not disclosed

Quick read

  • Revenue grew 406.9% year over year.
  • Operating loss of $34.5M in 2025.

Last 3 years

Revenue
$4.4M2024$22.2M2025
Operating income
-$46.3M2024-$34.5M2025

See the share price on Google Finance ↗

Investor metrics

2025
Operating margin
-155.3%
Net margin
-147.0%
ROE
-59.7%
Debt-to-equity
20.4%
Equity ratio
83.1%

USD at SEK 10.18 per $1 (2026-11-20, ExchangeRate-API)

Staff costs from the annual report (wages, social charges, pensions) divided by the average number of employees. Usually higher than take-home pay.

audited consolidated financial statements · View the annual report (filings.xbrl.org)

Not investment advice. Figures come from public filings and may contain errors.